ULC1633T_S98
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.440
- PROTEIN_SECRETION+0.400
- MYC_TARGETS_V1+0.350
- ADIPOGENESIS+0.340
- GLYCOLYSIS+0.320
- PEROXISOME+0.310
- MTORC1_SIGNALING+0.300
- PANCREAS_BETA_CELLS+0.300
- DNA_REPAIR+0.280
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.280
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.180
- WNT_BETA_CATENIN_SIGNALING-0.160
- APICAL_SURFACE-0.110
- HEDGEHOG_SIGNALING-0.100
- INTERFERON_GAMMA_RESPONSE-0.100
- INTERFERON_ALPHA_RESPONSE-0.090
- MITOTIC_SPINDLE-0.090
- KRAS_SIGNALING_DN-0.080
- SPERMATOGENESIS-0.070
- ALLOGRAFT_REJECTION-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | f34c57ee-92a6-4e3b-acde-7fd631c42f87 | — | — | 0.816 |
| 2 | SRR1516101 | — | — | 0.798 |
| 3 | 0e1c98de-b4e2-4f42-beca-9948f867a46b | — | — | 0.773 |
| 4 | c86cd6e5-cb8f-40d1-95ac-2fda1d309808 | — | — | 0.763 |
| 5 | SRR6013489 | — | cohortA1 | 0.750 |
| 6 | TCGA-73-4670-01A-01R-1206-07 | — | cohortA4 | 0.749 |
| 7 | c119f5ef.864c.434b.b515.57c27c7ae949 | — | cohortA1 | 0.744 |
| 8 | MNG590 | — | — | 0.738 |
| 9 | TCGA-73-4676-01A-01R-1755-07 | — | cohortA1 | 0.737 |
| 10 | SRR6013485 | — | cohortA4 | 0.726 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.440 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.340 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.320 | Inavolisib | — uncovered |
| PEROXISOME | 0.310 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| DNA_REPAIR | 0.280 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.280 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.250 | Inavolisib | — uncovered |
| COAGULATION | 0.220 | Binimetinib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.190 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.180 | Idelalisib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.160 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.150 | Inavolisib | — uncovered |